Mekonos closes funding of $25M in a series a round as it develops the future of cell therapies on a chip. The Biotech Company has developed a platform that is able to support the multiple delivery of cell payloads right down to the cell level, and allows for the physical delivery of these payloads.
Biotech Startup Mekonos raises oversubscribed $25 million after prominent research labs had promising results for the company’s developed platform for chip technology. The delivery system for the payload will be ex-vivo.
As Mekonos closes funding it has revealed plans for the use of this acquired capital. The company is planning to venture into business development, Microfluidics, MEMS among other areas.
The future of cell therapies on a chip shows the excellent ability to provide repeated and measured doses, such as CRISPR, into vulnerable cell types that include stem cells.
With this latest funding, Mekonos plans to bring change to cell therapy, an area that has not witnessed innovation in over two decades. Mekonos official stated that they are keen on disrupting existing technology in cell engineering and are making an effort to delve into personalized medicine on a large scale.
